DC Chemicals Limited
China
Product Name: Ambenonium dichloride tetrahydrate
Price: ￥Inquiry/100mg ￥Inquiry/250mg ￥Inquiry/1g
Purity: 98.0%
Stocking Period: 10 Day
Contact: Tony Cao

52022-31-8

52022-31-8 structure

Name: 2,2'-[(1,2-Dioxo-1,2-ethanediyl)diimino]bis[N-(2-chlorobenzyl)-N, N-diethylethanaminium] dichloride
Chemical Name: 2,2'-[(1,2-Dioxo-1,2-ethanediyl)diimino]bis[N-(2-chlorobenzyl)-N, N-diethylethanaminium] dichloride
CAS Number: 52022-31-8
Molecular Formula: C₂₈H₄₂Cl₄N₄O₂
Molecular Weight: 608.47100
Catalog: Signaling Pathways Neuronal Signaling AChE
Create Date: 2016-05-12 22:12:26
Modify Date: 2024-02-18 21:20:55
Ambenonium (WIN 8077) dichloride tetrahydrate is an orally active and reversible inhibitor of Acetyicholinesterase (AChE) with high affinity. Ambenonium dichloride tetrahydrate inhibits human AChE with an IC50 value of 0.7 nM (hAChE)[1][2].

Name	2,2'-[(1,2-Dioxo-1,2-ethanediyl)diimino]bis[N-(2-chlorobenzyl)-N, N-diethylethanaminium] dichloride

Description	Ambenonium (WIN 8077) dichloride tetrahydrate is an orally active and reversible inhibitor of Acetyicholinesterase (AChE) with high affinity. Ambenonium dichloride tetrahydrate inhibits human AChE with an IC50 value of 0.7 nM (hAChE)[1][2].
Related Catalog	Research Areas >> Neurological Disease Signaling Pathways >> Neuronal Signaling >> AChE
Target	Acetylcholinesterase:0.7 nM (IC50) Acetylcholinesterase:0.12 nM (Ki) Butyrylcholinesterase:7 μM (IC50)
In Vitro	Ambenonium dichloride tetrahydrate inhibits Acetyicholinesterase (AChE) in a rapidly reversible method, and shows strong inhibition with inhibition constant Ki of 0.12 nM against hAChE[1]. Ambenonium dichloride tetrahydrate shows inhibitory effect towards BChE with an IC50 value of 7 μM (hBChE)[2].
In Vivo	Ambenonium dichloride tetrahydrate (6 mg/kg; p.o.; daily; 30-60 d) results an adverse effect on neuromuscular transmission in long-term administration, and induces hypersensitivity to stimulation in myasthenia gravis mice modle[3]. Ambenonium dichloride tetrahydrate (6 mg/kg; p.o.; daily; 14 d) decreases the number of AChR in motorend-plates[3]. Animal Model: Female Sprague Dawley rats (weight 250 g) with myasthenia gravis[3] Dosage: 6 mg/kg Administration: Oral gavage; daily; 14, 30, 60, 90, 360 days (Stop administration 24 h in advance) Result: Resulted general activity decreasing and hypersensity to stimulation in rats during day 30-60, but these behaviors disappeared on day 90. Induced degeneration and simplification of the postsynaptic folds, widening of the synaptic clefts, increased number of the postsynaptic vesicles, and reduction in the number of the AChR in the postsynaptic membrane on day 360.
References	[1]. Hodge AS, et al. Ambenonium is a rapidly reversible noncovalent inhibitor of acetylcholinesterase, with one of the highest known affinities. Mol Pharmacol. 1992 May. 41(5):937-42. [2]. Komloova M, et al. Preparation, in vitro screening and molecular modelling of symmetrical bis-quinolinium cholinesterase inhibitors--implications for early myasthenia gravis treatment. Bioorg Med Chem Lett. 2011 Apr 15. 21(8):2505-9. [3]. Hazama R, et al. Effects of long-term administration of ambenonium chloride on motor end-plate fine structure and acetylcholine receptor in rat. J Neurol Sci. 1981 Jul. 51(1):69-79.

Molecular Formula	C₂₈H₄₂Cl₄N₄O₂
Molecular Weight	608.47100
Exact Mass	606.20600
PSA	70.84000
LogP	7.66880

1158522-08-7	940364-43-2
1542983-68-5	1558142-01-0
134104-43-1	131615-57-1
6906-52-1	930439-75-1
1018584-77-4	1706460-48-1